Company Filing History:
7 out of 18 
1 out of 117 
1 out of 1 Years Active: 1998-2025
Title: Agneta Svedberg: Innovator in Cancer Treatment
Introduction
Agneta Svedberg is a prominent inventor based in Lund, Sweden. She has made significant contributions to the field of cancer treatment, particularly through her innovative work on antibodies targeting interleukin-1 receptor accessory protein (IL1RAP). With a total of nine patents to her name, Svedberg's research is paving the way for new therapeutic approaches in oncology.
Latest Patents
Among her latest patents, Svedberg has developed methods for treating IL1RAP associated cancers using anti-human interleukin-1 receptor accessory protein antibodies. This invention provides an antibody or an antigen-binding fragment that specifically binds to human IL1RAP, effectively inhibiting the binding of the antibody 'CAN04' to this protein. The applications of these antibodies extend to the treatment and diagnosis of IL-1 associated diseases, including acute myeloid leukemia and melanoma.
Career Highlights
Svedberg has worked with notable companies in the pharmaceutical industry, including Cantargia AB and Pharmacia & Upjohn. Her experience in these organizations has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Some of her notable coworkers include Helena Ågerstam and Thoas Fioretos. Their collaborative efforts have further advanced the research and development of innovative cancer treatments.
Conclusion
Agneta Svedberg's work exemplifies the impact of innovation in the medical field, particularly in cancer therapy. Her patents and collaborations highlight her commitment to improving patient outcomes through scientific advancements.